Strides Pharma gains after USFDA approves Pregabalin Capsule

29 Jan 2024 , 02:51 PM

Strides Pharma Science’s stock price rose a percent in early trading on January 29 after the firm announced that it received permission from the United States Food and Drug Administration (USFDA) to sell a generic medicine for nerve pain.

Strides Pharma Global Pte Limited, a subsidiary of the business, has acquired approval from the US drug agency for Pregabalin capsules in various strengths (25 mg, 50 mg, 75 mg, 150 mg, 100 mg, 200 mg, 225 mg, and 300 mg).

The product is bioequivalent and therapeutically equivalent to Upjohn US’s Lyrica pills, which are a Reference Listed Drug.  The capsule is used to treat fibromyalgia.

The business has 260 cumulative ANDA submissions with the USFDA (including the newly acquired portfolio from Endo at Chestnut Ridge), with over 235 ANDAs authorised.

Over the next three years, the business plans to launch 60 new goods in the United States.

At around 2.48 PM, Strides Pharma was trading 0.48% lower at Rs 683, against the previous close of Rs 686.30 on NSE.

For feedback and suggestions, write to us at [e-mail]